ARS Pharmaceuticals (SPRY) Leases: 2021-2025
Historic Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $1.4 million.
- ARS Pharmaceuticals' Leases rose 1464.13% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 1464.13%. This contributed to the annual value of $37,000 for FY2024, which is 85.20% down from last year.
- Per ARS Pharmaceuticals' latest filing, its Leases stood at $1.4 million for Q3 2025, which was down 7.99% from $1.6 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Leases ranged from a high of $5.0 million in Q3 2021 and a low of $37,000 during Q4 2024.
- Moreover, its 3-year median value for Leases was $250,000 (2023), whereas its average is $440,455.
- As far as peak fluctuations go, ARS Pharmaceuticals' Leases crashed by 91.12% in 2023, and later surged by 1,464.13% in 2025.
- Quarterly analysis of 5 years shows ARS Pharmaceuticals' Leases stood at $621,000 in 2021, then declined by 28.34% to $445,000 in 2022, then tumbled by 43.82% to $250,000 in 2023, then tumbled by 85.20% to $37,000 in 2024, then skyrocketed by 1,464.13% to $1.4 million in 2025.
- Its Leases stands at $1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and $72,000 for Q1 2025.